Hanyu Medical Raises ￥500 million in Series D Funding Round

According to VCBeat, on August 13, 2020, Hanyu Medical announced that it had completed a Series D financing of RMB500 million, led by Highlight Capital, CPE and Yingke Capital, with participation from ALAN AMC, Everest VC, Med-Fine Capital, Orient Securities Capital, TF Capital, Hefang Sci-Tech Venture Capital and Spring Fund. The funds raised will be used to promote the launch of Valve Clamp, the company's leading product, as well as the development of new products. Bairong Capital served as the exclusive financial adviser of the latest round.

Established in December 2016, Hanyu Medical is the first domestic company engaged in the research, development, production and sales of heart valve interventional medical devices.

According to Dai Yufeng, chairman of Hanyu Medical, "Valve Clamp, the core product of Hanyu Medical for mitral valve repair, is the first minimally invasive device for mitral valve interventions independently developed in China that has entered the pre-market clinical trial. At present, Valve Clamp's effect and superior performance have been highly evaluated and recognized by first-line experts."

"The field of mitral valve disease is the subdivision track with the highest incidence among valvular heart diseases. We are confident to develop rapidly in this track to provide more patients with more high-quality and effective treatment. At the same time, we have a number of products under development, committed to building a comprehensive platform for structural heart products," said Dai Yufeng.

HLC is a health industry focused fund. It is dedicated to investing in leading life science enterprises that provide innovative products and services to advance diagnosis and treatment of diseases and to promote healthy living. With extensive experience, the company has established a strong presence across sub-sectors such as biotechnology (innovative therapeutics, CRO/CMO, etc.), medical technology (medical devices, IVD, etc.) and consumer health (hospital chains, personal care, etc.).

CPE is a leading alternative asset manager, with asset classes spanning private equity, mezzanine and the public market. Founded in 2008 by a world-class team of investment professionals and supported by over 200 domestic and international investors, the firm uses its sector expertise to generate deal flow and drive the value creation work during the post-investment stage.